The North America Continuous Manufacturing Market was valued at USD 1,420 Million in 2025 and is projected to reach USD 4,950 Million by 2035, growing at a CAGR of 12.5% from 2024 to 2035. The continuous manufacturing sector is evolving rapidly as pharmaceutical and chemical companies prioritize efficiency, flexibility, and sustainability. Technological advancements and adoption by leading industry players are expected to drive robust market growth throughout the forecast period.
The economic impact of tariffs on "North America Continuous Manufacturing Market".
Market Growth Drivers
Increased Adoption by Major Pharmaceuticals: In recent years, key pharmaceutical companies such as Pfizer and Johnson & Johnson have significantly scaled up investments in continuous manufacturing to streamline production processes and minimize costs. For instance, in 2023, Johnson & Johnson announced the expansion of its continuous manufacturing capacity for critical drug products in North America, aiming to enhance supply chain resilience and fast-track product launches. This strategic emphasis on reliability and flexibility has incentivized further industry adoption.
Regulatory Push Towards Quality and Efficiency: Regulatory agencies like the US FDA have played a pivotal role by providing clear guidelines and incentives for continuous manufacturing. The FDA's Emerging Technology Program (ETP) and recent approvals for continuous manufacturing processes—such as Eli Lilly's Verzenio in 2023—underscore growing regulatory confidence. This regulatory backing not only simplifies compliance but also accelerates approvals and market entry, further bolstering market growth.
Market Trends
Integration of Automation and Digitalization: Companies are increasingly implementing Industry 4.0 technologies, such as advanced automation, real-time analytics, and AI-based process optimization, in their continuous manufacturing lines. For example, Thermo Fisher Scientific introduced a fully automated continuous pharmaceutical manufacturing platform in early 2024, offering enhanced yield, real-time quality monitoring, and reduced operational risk. These trends are driving efficiency and accuracy across production.
Expansion of Modular and Flexible Facilities: Modular continuous manufacturing facilities have gained traction as they enable scalable and adaptable production capacities. In 2024, Merck (MSD) inaugurated a modular continuous manufacturing plant in Pennsylvania, aimed at accelerating launch timelines for new therapies. This modular approach allows faster adaptation to market dynamics and reduces overall capital expenditures, setting a trend for flexible facility designs in North America.
Market Opportunities
Personalized Medicine Production: With the rise of precision medicine, continuous manufacturing offers the flexibility needed for small-batch and personalized drug production. Companies like Moderna are leveraging continuous manufacturing to accelerate personalized vaccine production workflows, presenting a lucrative opportunity in this evolving therapeutic landscape.
Green Manufacturing Initiatives: Environmental sustainability is becoming a top priority, and continuous manufacturing technologies contribute by reducing waste and energy consumption. Companies such as Amgen are investing in greener continuous processes to meet stringent emission targets, presenting opportunities for strategic differentiation in the market.
North America Continuous Manufacturing Market Revenue (USD Million), 2020-2035
The market revenue chart illustrates steady growth in the North America Continuous Manufacturing Market from 2020 to 2035. In 2020, the market revenue stood at USD 700 Million and saw a notable increase driven by early adoption across pharmaceuticals. By 2025, the market is projected to reach USD 1,420 Million, reflecting increased investments and technology integration. Post-2025, the market enters a rapid growth phase, fueled by policy incentives and scaling up by large enterprises, culminating at USD 4,950 Million by 2035. The upward trajectory underscores strong demand and broadening industry acceptance across North America.
North America Continuous Manufacturing Market by Regions Share (%), 2025
The market share pie chart for 2025 shows that the United States dominates with a 68% share, reflecting its established pharmaceutical infrastructure and ongoing investments in technology. Canada follows with 18%, propelled by government incentives and a strong R&D pipeline. Mexico accounts for 8%, largely due to the growth of its generics and contract manufacturing sectors. Other North American regions including Puerto Rico and Rest of North America contribute smaller shares of 4% and 2% respectively, indicative of their nascent but growing participation in the market. The chart highlights continued US leadership in innovation and capacity.
Recent Developments
In May 2024, Pfizer announced a partnership with GEA Group to develop and deploy next-generation continuous manufacturing platforms in its North American production sites. This collaboration aims to improve operational agility, reduce downtime, and ensure faster market delivery of new drugs. The project is set to incorporate advanced automation, AI-driven monitoring, and advanced analytics to further establish Pfizer’s leadership in digital transformation.
In April 2024, Thermo Fisher Scientific unveiled its new Process Analytical Technology (PAT)-integrated continuous manufacturing suites. These suites are tailored for the pharmaceutical industry, featuring real-time quality assurance, minimal manual intervention, and seamless scalability. The announcement was met with positive industry response, with several biopharmaceutical firms expressing interest in adopting Thermo Fisher’s modular and digitalized solution.
In March 2024, the US FDA granted approval to Eli Lilly’s continuous manufacturing protocol for its leading oncology product line at its Indianapolis plant. The approval followed a successful pilot phase demonstrating improved yield and quality consistency. The development signifies a progressive shift in regulatory openness toward continuous manufacturing, potentially accelerating industry-wide adoption.
Press Releases